Because TIM-1 is recognized as a therapeutic target in cancers, kidney injury, and immune diseases [58,59,60], we believe that developing potent TIM-1 inhibitors might be a promising possibility for successful anti-DENV and anti-viral drugs in the future. The gene discussed is HAVCR1; the disease is immune system disorder.